Rezdiffra (Resmetirom) for NASH F2-F3: Dosing Protocol, Evidence, and Clinical Guidance

What Is Resmetirom and How Did It Gain FDA Approval?

Resmetirom (brand name Rezdiffra) is a first-in-class, oral, liver-directed THR-β agonist developed by Madrigal Pharmaceuticals. The FDA granted it accelerated approval on March 14, 2024, making it the first drug ever approved specifically for NASH (metabolic dysfunction-associated steatohepatitis, or MASH under updated nomenclature) with moderate-to-severe hepatic fibrosis in adults without cirrhosis [1].

The approval rested on histologic surrogate endpoints from the Phase 3 MAESTRO-NASH trial, not on long-term clinical outcomes like decompensated cirrhosis or liver transplantation. This distinction matters. Accelerated approval means the drug reached patients faster, but Madrigal must complete confirmatory outcome data (MAESTRO-NASH Part 2, a 54-month extension) to convert it to full traditional approval [2]. The FDA's prescribing information states this explicitly: continued approval may be contingent on verification of clinical benefit.

THR-β agonism works by activating thyroid hormone receptor beta selectively in the liver, which drives mitochondrial fatty acid oxidation and reduces hepatic lipid accumulation, inflammation, and fibrogenesis. Unlike nonselective thyroid hormone analogs, resmetirom avoids THR-α-mediated cardiac and bone effects [3]. The result is targeted hepatic fat reduction with a manageable systemic safety profile.

Is Resmetirom "Off-Label" for F2-F3 NASH, or Is That the Approved Indication?

This point requires clarification because it generates confusion. Resmetirom is FDA-approved specifically for noncirrhotic NASH with F2-F3 fibrosis. Prescribing it within this population is on-label use [1]. The "off-label" question arises in two scenarios: using resmetirom in F0-F1 fibrosis (early-stage NASH without significant fibrosis) or in F4 fibrosis (compensated cirrhosis). Neither of these populations was included in the approval.

The FDA label is narrow by design. MAESTRO-NASH enrolled adults aged 18 and older with biopsy-confirmed NASH, a nonalcoholic fatty liver disease activity score (NAS) of 4 or higher, and fibrosis stage F2 or F3 on the NASH CRN scoring system [2]. Patients with F4 (cirrhosis), decompensated liver disease, or hepatocellular carcinoma were excluded.

True off-label use would include prescribing resmetirom for patients with F1 fibrosis and active steatohepatitis, patients with compensated cirrhosis (F4), or non-NASH fatty liver disease such as alcohol-associated steatohepatitis. No randomized controlled trial evidence supports these uses at this time. The American Association for the Study of Liver Diseases (AASLD) practice guidance from 2023 addressed pharmacotherapy for NASH but predated resmetirom's approval; updated guidance incorporating it is anticipated.

For clinicians considering truly off-label prescribing (F1 or F4 populations), the evidence level is very low (GRADE: very low certainty), supported only by mechanistic rationale and subgroup post-hoc analyses that were not powered for those fibrosis stages.

MAESTRO-NASH Trial: Primary Evidence for the F2-F3 Population

The MAESTRO-NASH trial (NCT03900429) was a randomized, double-blind, placebo-controlled Phase 3 study that enrolled 966 adults with biopsy-confirmed NASH and F2 or F3 fibrosis across 200 sites globally [2].

Patients were randomized 1:1:1 to resmetirom 80 mg daily, resmetirom 100 mg daily, or placebo. The two co-primary endpoints at Week 52 were:

1. NASH resolution with no worsening of fibrosis. This required a NAS ballooning score of 0, lobular inflammation score of 0 or 1, and no increase in fibrosis stage. Results: 25.9% (80 mg), 29.9% (100 mg), vs. 9.7% (placebo). Both active arms achieved statistical significance (P<0.001 for each vs. placebo) [2].

2. Fibrosis improvement by ≥1 stage with no worsening of NAS. Results: 24.2% (80 mg), 25.9% (100 mg), vs. 14.2% (placebo). The 100 mg arm was statistically significant (P<0.001); the 80 mg arm also reached significance (P = 0.002) [2].

A secondary endpoint, the combination of NASH resolution plus fibrosis improvement, occurred in 12.4% (80 mg) and 15.5% (100 mg) vs. 5.2% (placebo). These dual-response rates, while modest in absolute terms, represent a meaningful step given that no prior drug had achieved this in a Phase 3 NASH trial.

The New England Journal of Medicine publication by Harrison et al. (2024) reported that LDL cholesterol dropped by approximately 16% from baseline in the 100 mg group, an effect consistent with THR-β-mediated upregulation of hepatic LDL receptors [4]. Triglycerides and lipoprotein(a) also decreased significantly. This lipid-lowering profile may carry independent cardiovascular benefit in a population already burdened by cardiometabolic risk.

Dr. Stephen Harrison, the trial's lead investigator, noted: "For the first time, we have a drug that addresses both the hepatic inflammation and the fibrosis that drive progression to cirrhosis in NASH patients" [4].

Dosing Protocol: Weight-Based Selection and Administration

The approved dosing protocol is straightforward and weight-stratified [1]:

• Body weight <100 kg: 80 mg orally once daily with food
• Body weight ≥100 kg: 100 mg orally once daily with food

Tablets should be swallowed whole. The drug reaches steady state within approximately 7 days, with a terminal half-life of roughly 40-50 hours. The weight-based cutoff reflects pharmacokinetic modeling showing that patients at higher body weight achieve lower drug exposure at 80 mg, and the 100 mg dose compensates for this difference [1].

No dose titration is required. Unlike GLP-1 receptor agonists, which require weeks-long escalation to mitigate gastrointestinal side effects, resmetirom starts at the target dose from Day 1. This simplifies the prescribing workflow and accelerates time to therapeutic exposure.

There are specific contraindications and precautions. The label carries warnings about hepatotoxicity, and the drug should not be used in patients with decompensated cirrhosis (Child-Pugh B or C). Liver function tests (ALT, AST, bilirubin) should be obtained at baseline, during treatment, and as clinically indicated. Gallbladder-related adverse events occurred more frequently in resmetirom-treated patients in MAESTRO-NASH: cholelithiasis (2.4% vs. 0.6% placebo) and cholecystitis (0.9% vs. 0.3% placebo) [2].

Drug interactions are relatively limited. Resmetirom is metabolized primarily by CYP2C8 and CYP3A4. Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase resmetirom exposure and should be avoided. Concomitant use with statins is permitted and was common in the trial population, with no dose adjustment required for either drug [1].

Safety Profile: What MAESTRO-NASH and MAESTRO-NAFLD-1 Showed

The safety database for resmetirom spans two large Phase 3 trials. MAESTRO-NASH provided the efficacy and safety data for the F2-F3 population (n=966 randomized), while MAESTRO-NAFLD-1 (n=2,000+) was a larger, longer safety study in a broader NAFLD population [5].

In MAESTRO-NASH, the most common adverse events with resmetirom 100 mg vs. placebo were diarrhea (33.0% vs. 17.1%), nausea (21.7% vs. 13.2%), and abdominal pain (6.5% vs. 5.3%). Most GI events were mild-to-moderate and occurred within the first few weeks of treatment [2]. Serious adverse events occurred at similar rates across groups (approximately 10-12%).

A finding that drew regulatory attention: a small, non-significant numerical increase in serious liver-related events in the resmetirom arms. The FDA advisory committee discussed this at length during the October 2023 meeting and concluded that the benefit-risk profile favored approval, with the requirement for ongoing post-marketing surveillance [1].

The AASLD's Dr. Mary Rinella stated during a 2024 commentary: "Resmetirom's safety profile is reassuring in the F2-F3 population, but we need the 54-month outcomes data to fully characterize long-term hepatic and cardiovascular effects" [6].

Thyroid function remained stable in resmetirom-treated patients. TSH levels did not change significantly, and free T4 and free T3 remained within normal limits, consistent with the liver-directed THR-β selectivity of the drug [4]. This is a frequent clinical question and a point of differentiation from older, nonselective thyroid hormone mimetics.

Monitoring and Follow-Up for Prescribers

Practical monitoring in a clinical or telehealth setting involves several considerations:

Baseline requirements before starting resmetirom:

• Liver biopsy confirming NASH with F2 or F3 fibrosis (required for on-label use)
• Comprehensive metabolic panel including ALT, AST, total bilirubin, and albumin
• Lipid panel (LDL-C, triglycerides, lipoprotein(a) if available)
• TSH and free T4
• Assessment for gallbladder disease history

On-treatment monitoring:

• LFTs at Weeks 4, 12, and every 3-6 months thereafter (per clinical judgment)
• Lipid panel at 12 weeks and then annually
• Thyroid function tests if symptoms of thyroid dysfunction develop
• Monitoring for GI symptoms, especially in the first 4-8 weeks
• Gallbladder symptom screening at follow-up visits

The question of repeat biopsy is unresolved. The FDA label does not mandate a follow-up liver biopsy, but some hepatologists recommend one at 12-18 months to assess histologic response, particularly if the decision to continue therapy depends on demonstrated improvement. Non-invasive tests such as FibroScan (vibration-controlled transient elastography), enhanced liver fibrosis (ELF) score, and FIB-4 index can track trends but have not been validated as surrogate endpoints for resmetirom response specifically [6].

How Resmetirom Compares to Other NASH Therapeutics

The NASH treatment field has expanded. Resmetirom was first to approval, but several other agents target overlapping or complementary pathways.

Semaglutide (Ozempic/Wegovy): The STEP-NASH trial is evaluating semaglutide for NASH with fibrosis. In the earlier Phase 2 trial by Newsome et al. (2021), semaglutide 0.4 mg daily achieved NASH resolution in 59% of patients at 72 weeks vs. 17% placebo, but fibrosis improvement did not reach significance [7]. Semaglutide addresses metabolic drivers (insulin resistance, weight, adiposity) but does not directly target hepatic THR-β signaling.

Obeticholic acid (Ocaliva): The FXR agonist reached Phase 3 (REGENERATE trial) and showed fibrosis improvement in 23% vs. 12% placebo at 18 months, but NASH resolution rates were not significantly different, and pruritus affected over 50% of patients [8]. Intercept withdrew its FDA application in 2023 after a complete response letter.

Lanifibranor: A pan-PPAR agonist in Phase 3 (NATiV3 trial) that addresses steatosis, inflammation, and fibrosis through a different mechanism. Head-to-head data against resmetirom do not exist.

Resmetirom's advantage is its dual histologic benefit (both NASH resolution and fibrosis improvement) combined with an oral once-daily formulation and tolerable side effect profile. Its lipid-lowering effects add value in a population where cardiovascular disease is the leading cause of mortality, exceeding liver-related death in patients with NASH up to F3 fibrosis [9].

Who Should Not Receive Resmetirom

The prescribing information and clinical evidence define clear exclusions [1]:

• Decompensated cirrhosis (Child-Pugh B or C)
• Known hypersensitivity to resmetirom or any excipient
• Concomitant use of strong CYP2C8 inhibitors (gemfibrozil is the primary concern)
• Pregnancy (animal data showed fetal harm at supratherapeutic doses; no human data available)
• Active gallbladder disease (cholelithiasis, cholecystitis) warrants risk-benefit discussion

Patients with compensated cirrhosis (F4, Child-Pugh A) were excluded from MAESTRO-NASH. Using resmetirom in this group is off-label with no controlled data supporting safety or efficacy. A Phase 2 study (MAESTRO-NASH-2) explored this population, but results have not been published in a peer-reviewed journal as of May 2026.

Cost, Access, and Insurance Coverage

Rezdiffra's wholesale acquisition cost (WAC) is approximately $47,400 per year [10]. This price point has generated significant payer scrutiny. Most commercial insurers require prior authorization with documentation of biopsy-confirmed NASH and F2-F3 fibrosis before coverage approval. Some plans impose step therapy requirements (e.g., documented failure or contraindication to lifestyle intervention and/or pioglitazone or vitamin E before approving resmetirom).

Madrigal launched a patient assistance program (Rezdiffra Complete) offering copay support for commercially insured patients and free drug for qualifying uninsured patients. Medicare Part D coverage varies by plan and formulary tier.

The cost-effectiveness of resmetirom is under active evaluation. A 2024 Institute for Clinical and Economic Review (ICER) preliminary report estimated that resmetirom met commonly cited willingness-to-pay thresholds only if the 54-month confirmatory data demonstrate a reduction in progression to cirrhosis and liver-related events. Without confirmed long-term outcomes, the value-based price estimate was substantially lower than the WAC.